Published: 2022-07-27

Study on awareness of human papillomavirus vaccine

Arunkumar P., Kohila K.


Background: Cervical cancer is the second most common cancer among women in India. Despite the various interventions, prevention is always better than cure. vaccination is the most effective way of preventing it. The objective of this study was to assess the knowledge, attitude and practice related to HPV vaccination among adolescents and reproductive age women.

Methods: The data collected were used for the study. It was a community based cross sectional study involving 201 women as study participants who attended the obstetrics and gynecology department of Saveetha Medical College Hospital during the period of January 2022-March 2022 using a pretested, semi structured questionnaire tool.

Results: Among the study population, 64.7% had knowledge about cervical cancer and 62.2% knew about vaccines and their effects. More than 60% of the study population were willing to get vaccinated.

Conclusions: As a primordial prevention, we should create awareness among young population to get vaccinated against HPV, and sexually active women to take pap smear. This will prevent the incidence of cervical cancer in India.


OCPs, Multiple pregnancies, Pap smear

Full Text:



World Health Organization, Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020.

Miller AB, World Health Organization. Cervical cancer screening programmes: managerial guidelines. World Health Organization. 1992

Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Internal Med. 2009;151(8):538-45.

Abdullahi A, Copping J, Kessel A, Luck M, Bonell C. Cervical screening: Perceptions and barriers to uptake among Somali women in Camden. Public Health. 2009;123:680-5.

Mukama T, Ndejjo R, Musabyimana A, Halage AA, Musoke D. Women's knowledge and attitudes towards cervical cancer prevention: A cross sectional study in Eastern Uganda. BMC Womens Health. 2017;17:9.

Chande HM, Kassim T. Assessment of women's knowledge and attitude towards carcinoma of the cervix in Ilala Municipality. East Afr J Public Health. 2010;7:74-7.

Juntasopeepun, Davidson P, Suwan PM, Phianmongkhol N. Human Papillomavirus Vaccination Intention among Young Women in Thailand. Asian Pacific J Can Preven. 2011;12(12):3213-9.

Montgomery MP, Dune T, Shetty PK, Shetty AK. knowledge and Acceptability of Human Papillomavirus Vaccination and Cervical Cancer Screening among Women in Karnataka. Ind J Can Educ. 2015;30(1):130-7.

Charakorn C, Rattanasiri S, Lertkhachonsuk AA Thanapprapasr D, Chittithaworn S, Wilailak S. knowledge of Pap smear, HPV and HPV vaccine and the acceptability of HPV vaccine by Thai women. Asia-Pacific J Clin Onco. 2011;7(2):160-7.

Basu P, Sarkar S, Mukherjee S. Women’s perceptions and social barriers determine compliance to cervical screening: Results from a population-based study in India. Can Detect Prev. 2016;30(4):369-74.

Bruni L, Albero G, Serrano B, Mena M, Gomez D, Munoz J et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information centre). Human Papillomavirus and Related Diseases in India. Summary Report. 2019.

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2018.

National Centre for Disease Informatics and Research, National Cancer Registry Programme, ICMR. Time trends in cancer incidence rates, Bangalore, India: NCDIR-NCRP (ICMR). 2013.

Kumar NA, Ramnath T, Chaturvedi M. The magnitude of cancer in India. Indian J Med Res. 2009;130(3):219-21.

Plummer M. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609-16.

Ferris D, Samakoses R, Block SL. Long term Study of a Quadrivalent Human Papillomavirus Vaccine. Paediatr. 2014;134(3):e657-65.

Human Papillomavirus Vaccines: WHO position. 2017.

Schwarz TF. 10 year follow up on immunogenicity and safety of the Human Papillomavirus 16/18 As04- Adjuvanted vaccine administered to 10-4 years old girls. Abstract at WSPID, Rio de Janeiro. 2015.

Nygard M. evaluation of the long term Anti-Human Papillomavirus 6,11, 16 and 18, Immune response Generated by the Quadrivalent HPV vaccine. Clin Vac Immuno. 2015;22(8):943-8.

Andrade C, Menon V, Ameen S, Praharaj SK. designing and conducting knowledge, attitude and practice surveys in psychiatry: Practical guidance. Indian J Psychol Med. 2020;42(5):478-81.